Association between misoprostol and nonsteroidal anti‐inflammatory drug‐induced kidney injury: A systematic review and meta‐analysis

Abstract

AbstractAimsMisoprostol is a prostaglandin E1 analogue that is used to prevent nonsteroidal anti‐inflammatory drug (NSAID)‐induced gastrointestinal disorders. The aim of this systematic review and meta‐analysis was to evaluate whether use of misoprostol also decreases the risk of NSAID‐induced kidney injury.MethodsRandomized controlled trials that compared misoprostol vs. placebo in an adult patient population were selected. The primary outcome was kidney injury and the secondary outcome was severe adverse events. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach.ResultsTwelve studies were eligible for inclusion. Although the rates of kidney injury and severe adverse events did not differ significantly between misoprostol and placebo, a posthoc subgroup analysis that excluded studies in which different NSAIDs were used in the misoprostol and placebo groups suggested that misoprostol may reduce the risk of NSAID‐induced kidney injury (risk difference −0.09, 95% confidence interval −0.15 to −0.03, P < .01, I2 = 87%; evidence of very low certainty).ConclusionThere is limited evidence that misoprostol reduces the risk of NSAID‐induced kidney injury. Misoprostol possibly contributes to reducing the risk of kidney injury associated with chronic NSAID use. The findings of this meta‐analysis suggest further high‐quality clinical trials are warranted.